Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.49 |
| ▸ | TEK | Q02763 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072184 | 0.93 | ALK (0.56) | MAPK1ALKTEKKDREPHB4 | |
| SCHEMBL2724196 | 0.89 | MAPK1 (0.49) | MAPK1ALKTEKKDREPHB4 | |
| SCHEMBL10071987 | 0.86 | MAPK1 (0.52) | MAPK1ALKTEKKDREPHB4 | |
| SCHEMBL721547 | 0.84 | ALK (0.67) | ALKTEKKDREPHB4 | |
| SCHEMBL10071992 | 0.84 | ALK (0.59) | MAPK1ALKTEKKDREPHB4 | |
| SCHEMBL10071990 | 0.84 | ALK (0.55) | MAPK1ALKTEKKDREPHB4 | |
| SCHEMBL10072182 | 0.84 | MAPK1 (0.49) | MAPK1ALKTEKKDREPHB4 | |
| SCHEMBL2733285 | 0.84 | MAPK1 (0.59) | MAPK1ALKTEKKDREPHB4 | |
| SCHEMBL721229 | 0.77 | ALK (0.77) | ALKTEKKDREPHB4 | |
| SCHEMBL10104624 | 0.76 | ALK (0.60) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635581-B1 | 7-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-8865715-B2 | Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines | MERCK PATENT GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865715-B2 | Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines | MERCK PATENT GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| WO-2012059171-A1 | 7-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | PDK1, PDK2, PDK3 | MAPK1 182/4885ALK 2200/4885TEK 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.